CHP
DNTH icon

Cable Hill Partners’s Dianthus Therapeutics DNTH Stock Holding History

Cable Hill Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-63
Closed -$16K – 258
2019
Q1 		$16K Hold
63
– – 0.01% 408
2018
Q4 		$6K Buy
63
+57
+950% +$7.77K ﹤0.01% 526
2018
Q3 		$1K Buy
+6
New +$1.26K ﹤0.01% 742

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Cable Hill Partners's DNTH Position: Q2 2019 in Review

Cable Hill Partners sold out of Dianthus Therapeutics (DNTH) in Q2 2019, closing a stake of 63 shares — an estimated $16K sold.

Cable Hill Partners first reported a position in DNTH in Q3 2018 and held it in 3 quarters. The position peaked at $16K in Q1 2019. 70 funds tracked by Wall St. Rank hold DNTH as of Q2 2019.

  • Cable Hill Partners reported no remaining Dianthus Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Cable Hill Partners sold 63 Dianthus Therapeutics shares in Q2 2019, an estimated $16K.
  • Cable Hill Partners first reported a position in Dianthus Therapeutics in Q3 2018 and held it in 3 quarters.
  • Cable Hill Partners's Dianthus Therapeutics position peaked at $16K in Q1 2019.
  • 70 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.